Purdue Pharma v. Accord Healthcare: Supreme Court Denies Certiorari
Purdue Pharma sought U.S. Supreme Court review of lower-court rulings against three tamper-resistant opioid dosage form patents (US9763886, US9763933, US9775808). The Court denied the petition in 159 days, leaving the underlying adverse decision intact and Accord Healthcare’s path to market unobstructed by these patents.
Supreme Court shuts door on Purdue’s tamper-resistant opioid patent bid
Purdue Pharma filed a petition for a writ of certiorari in the U.S. Supreme Court on April 30, 2025, seeking review of adverse lower-court decisions concerning three patents — US9763886B2, US9763933B2, and US9775808B2 — each directed to tamper-resistant formulations of opioid dosage forms. The named defendant, Accord Healthcare, Ltd., is a generic pharmaceutical manufacturer whose ANDA filing triggered the underlying infringement dispute. Latham & Watkins represented Purdue, with Gregory George Garre as lead counsel; McAndrews, Held & Malloy represented Accord.
The Supreme Court denied the petition on October 6, 2025, closing the case in 159 days. A denial of certiorari is not a ruling on the merits — it signals only that fewer than four Justices voted to grant review. The practical consequence, however, is dispositive: the lower-court judgment adverse to Purdue’s patents stands as final, and Accord Healthcare faces no further appellate obstacle from this litigation stream on these three patents.
The 159-day timeline from filing to denial is consistent with standard Supreme Court certiorari processing, suggesting no extraordinary conference consideration or relisting. The public record does not disclose the grounds Purdue raised in its petition or the specific legal question presented. What remains unknown is whether parallel PTAB proceedings, other circuit-level appeals, or separate ANDA litigations involving these patents remain active — factors that could materially affect the enforceability picture for both parties.
Filing to Petition Dismissed in 159 days
159 days from filing to denial — notably swift for Supreme Court certiorari review
Supreme Court cert denial: what it means for both parties
Cert denied is not a merits ruling — but the effect is final
A denial of certiorari means the Supreme Court declined to exercise discretionary jurisdiction. The Court does not explain denials, and a denial carries no precedential weight on the underlying legal questions. Nevertheless, the practical outcome is that the lower court’s judgment — adverse to Purdue’s patent position — becomes the final word in this litigation chain. Purdue has exhausted federal appellate remedies on these three patents in this case.
Certiorari deniedPurdue’s patent enforcement path on these claims is closed
For Purdue Pharma, the denial forecloses further federal appellate review of the lower-court ruling in this case. The three tamper-resistant formulation patents cannot be reinstated through this litigation stream. Purdue may still pursue separate enforcement actions or assert different claim sets, but any attempt to re-litigate the same issues against Accord on these patents faces significant estoppel and res judicata risks.
Enforcement path closedAccord Healthcare’s ANDA position strengthened on these patents
Accord Healthcare emerges from this litigation with the lower-court judgment in its favour affirmed by the Supreme Court’s refusal to disturb it. The three patents — US9763886, US9763933, and US9775808 — no longer present an appellate-level barrier to Accord’s generic tamper-resistant dosage form. Subject to any remaining regulatory or parallel litigation hurdles not visible in this record, Accord’s market entry risk on these specific claims is materially reduced.
Market entry risk reducedGeneric opioid makers gain certainty; branded tamper-resistant IP weakened
The denial strengthens the competitive position of generic manufacturers in the tamper-resistant opioid dosage form space. For other ANDA filers referencing similar formulations, the outcome suggests these Purdue patent claims may not withstand challenge. Branded manufacturers holding analogous tamper-resistant technology patents should assess their claim architecture in light of the lower-court reasoning that Purdue was unable to have reviewed.
Generic competition risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Purdue Pharma | Individual | Branded opioid manufacturer — holder of US9763886, US9763933 & US9775808Search in Eureka ↗ |
| Defendant | Accord Healthcare, Ltd. | Company | Generic pharmaceutical manufacturer challenging Purdue’s tamper-resistant formulation patentsSearch in Eureka ↗ |
| Plaintiff counsel | Gregory George Garre | Attorney | Counsel for Purdue PharmaSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing Purdue PharmaSearch in Eureka ↗ |
| Defendant counsel | Alejandro Menchaca | Attorney | Counsel for Accord Healthcare, Ltd.Search in Eureka ↗ |
| Defendant law firm | McAndrews, Held & Malloy Ltd. | Law Firm | Representing Accord Healthcare, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The Supreme Court’s one-word disposition — ‘Petition DENIED’ — carries no explanatory reasoning and establishes no precedent on the underlying patent law questions Purdue sought to raise. At the Supreme Court level, a cert denial reflects only the Court’s exercise of its discretionary docket; it does not constitute an endorsement or rejection of the lower court’s legal analysis. For practical purposes, however, the denial is dispositive: the judgment below stands, Purdue’s appellate remedies are exhausted in this case, and Accord Healthcare’s position on these three patents is legally settled.
US9763886, US9763933 & US9775808 — tamper-resistant opioid dosage forms
The three patents-in-suit — US9763886B2, US9763933B2, and US9775808B2 — share a common technology family directed to tamper-resistant pharmaceutical dosage forms, commonly associated with Purdue’s extended-release oxycodone product line. These patents cover formulation-level innovations designed to deter physical and chemical manipulation, such as crushing or dissolving, intended to prevent opioid abuse. Application numbers 15/413505, 15/413614, and 15/413635 suggest a cluster of continuation filings from a common parent, which is typical of Purdue’s layered patent strategy in this space.
The strategic significance of this patent family lies in Purdue’s longstanding use of formulation patents to extend market exclusivity for branded opioid products beyond primary compound patents. Tamper-resistant dosage form patents have been heavily litigated in ANDA proceedings across multiple generic challengers. The outcome here — where the Supreme Court declined to disturb adverse lower-court rulings — suggests that at least one court found these formulation claims either invalid or not infringed, creating meaningful freedom-to-operate space for generic competitors in the abuse-deterrent opioid market.
Should you run an FTO against US9763886, US9763933 & US9775808?
Any pharmaceutical company developing, filing ANDAs for, or commercialising tamper-resistant or abuse-deterrent extended-release opioid dosage forms should treat this patent cluster as a priority FTO item. While the cert denial weakens Purdue’s enforcement position in the Accord litigation, these patents may still be asserted against other ANDA filers in separate proceedings. The lower-court reasoning that survived certiorari review provides a roadmap, but does not guarantee identical outcomes in other district court or Federal Circuit proceedings.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US9763886, US9763933, and US9775808 against your formulation design, identify continuation and divisional family members not yet adjudicated, and surface parallel ANDA litigation activity referencing these patents. Given the layered continuation structure typical of Purdue’s portfolio, a single case outcome does not clear the entire claim family — Eureka’s portfolio mapping ensures your FTO covers the complete enforceability landscape.
Run a freedom-to-operate analysis on US9763886B2 to assess your product’s exposure
Run FTO in Eureka →Similar tamper-resistant pharma patent cases at the Supreme Court and Federal Circuit
Explore related ANDA infringement actions and abuse-deterrent opioid formulation patent disputes reviewed by U.S. federal appellate courts.
What this case signals for the tamper-resistant pharma IP landscape
Supreme Court cert denial on branded opioid formulation patents has direct implications for ANDA strategy and generic market entry timelines.
Cert denial finalises lower-court patent invalidity or non-infringement finding
When the Supreme Court denies certiorari, the lower-court judgment becomes final and unreviewable in this case. For IP teams monitoring the tamper-resistant opioid formulation space, the three Purdue patents — US9763886, US9763933, US9775808 — should now be treated as non-enforceable against Accord on the adjudicated claims. Scope analysis should account for this outcome in any FTO work.
Other generic filers should audit exposure to these three patents immediately
Generic manufacturers with pending or approved ANDAs referencing tamper-resistant opioid dosage forms should reassess whether these three patents remain a material litigation risk in parallel proceedings. The cert denial does not automatically resolve other pending cases, but it eliminates the legal uncertainty that a Supreme Court reversal might have created.
Pharma v Accord — key questions answered
The Supreme Court’s denial of Purdue’s certiorari petition means the Court declined to review the lower-court judgment adverse to Purdue’s three tamper-resistant dosage form patents. The denial is not a ruling on the merits — it establishes no precedent — but it is final: the lower-court decision stands and Purdue has exhausted appellate remedies in this case against Accord.
Three patents are asserted: US9763886B2, US9763933B2, and US9775808B2, corresponding to application numbers 15/413505, 15/413614, and 15/413635. All three are directed to tamper-resistant pharmaceutical dosage forms, a technology associated with Purdue’s abuse-deterrent extended-release opioid product line.
Not directly. A cert denial does not vacate or invalidate the patents — it only finalises the judgment in this specific case between Purdue and Accord. Other ANDA filers may still face assertion of these patents in separate proceedings. However, the affirmed lower-court reasoning carries persuasive weight and may inform other district court or Federal Circuit rulings on the same claim set.
Purdue Pharma was represented by Latham & Watkins LLP, with Gregory George Garre as lead counsel — a former U.S. Solicitor General with significant Supreme Court appellate experience. Accord Healthcare was represented by McAndrews, Held & Malloy Ltd., with Alejandro Menchaca as lead counsel.
The petition was filed on April 30, 2025, and denied on October 6, 2025 — a period of 159 days. This timeline is consistent with standard Supreme Court certiorari processing through the October Term opening conference cycle, and does not suggest any unusual deliberation such as relisting or a call for the views of the Solicitor General.
PatSnap Eureka searches patents and litigation data to answer instantly.